Content developed by Marie Fuzzati (IRCCS Mondino Foundation and France Parkinson) and Ludivine Breger (INSERM), in close collaboration with MIUR. For more information or for questions, please contact experimentalmodels@jpnd.eu.

General Information

Rat: Sprague-Dawley

These rats express the tetracycline-controlled transactivator under a constitutive promoter (CAG-tTA) and the human LRRK2 gene tagged with HA and under the control of a tretracycline-responsive element (TRE)-fused mini-cytomegalovirus promoter. In this model, the human LRRK2 gene is expressed in the absence of tetracycline or its derivatives (e.g. Doxycycline).

Endogenous rat LRRK2 : yes

Corresponding human genotype: LRRK2 is the greatest known genetic contributor to Parkinson’s disease.

Neurodegeneration

Dopamine Homeostasis

Inclusions

Motor Behaviours

Response to dopaminergic treatment

Non-applicable in the absence of motor impairment.

Non-motor Behaviours

Not reported

Electrophysiology

Not reported

Neuroinflammation

Not reported

The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases, in particular Alzheimer’s. Learn More